What is it like doing a deal in lockdown?
par Suzy Davis
Private equity investment in life sciences sector
Exploring some of the potential benefits and challenges for life sciences companies considering PE investment.
par plusieurs auteurs
4 de 6 Publications
COVID-19: Private equity investors and investor directors – dealing with distress
Owning artworks – the chimera of possessions?
par Camille Tassi
Newsletter Private Equity N°2 - 4e trimestre 2019
par plusieurs auteurs
Newsletter Private Equity N°1 - 3e trimestre 2019
par plusieurs auteurs
IP, divestments, fragmentation and the future: M&A in life sciences
par Emma Danks
Autumn Budget 2018: additional requirements introduced and holding period extended for Entrepreneurs' Relief
Corporate governance reforms and the impact for portfolio companies in 2018
par Debbie Cloake